How to Reconstitute Egrifta (Tesamorelin): Dosing Math for mg, mL, and Units

The Direct Answer

Reconstituting tesamorelin is arithmetic, not chemistry. The FDA-approved dose is 2 mg subcutaneously once daily for HIV-associated lipodystrophy. The brand kits (Egrifta, Egrifta SV) are reconstituted with the sterile water supplied in the package and used within a short window because that diluent has no preservative. Compounded tesamorelin from a pharmacy is usually reconstituted with bacteriostatic water, which contains benzyl alcohol as a preservative and generally supports a longer beyond-use period assigned by the compounding pharmacy rather than by the FDA label. In both cases, the number printed on the pharmacy label as mg/mL is the only number that matters for calculating your syringe draw, and it should be confirmed before every new vial is used, not assumed to match the last one.

That is the fact-dense core of this page: the dosing math is simple, the failure mode is not doing the math when the concentration changes, and the consequence of skipping that check is a two-fold (or larger) dosing error with no built-in alarm to catch it.

Why the Syringe Units Cause Confusion

A U-100 insulin syringe is printed in units, not milligrams or milliliters. One milliliter equals 100 units. If a plan calls for "20 units," that is 0.20 mL. What that 0.20 mL delivers in milligrams depends entirely on the concentration in the vial:

• At 1 mg/mL, 20 units (0.20 mL) delivers 0.20 mg.
• At 2 mg/mL, the same 20 units delivers 0.40 mg.

The syringe never tells you the concentration. Only the pharmacy label does.

The Core Formula

Dose (mg) ÷ Concentration (mg/mL) = Volume to inject (mL)

Volume (mL) × 100 = Units on a U-100 syringe

This two-step sequence applies to the brand kit and to any compounded vial, regardless of diluent.

Reconstitution as Described in FDA Labeling

Egrifta (original formulation)

The original Egrifta kit ships as two 1 mg vials with a supplied ampule of sterile water. According to the FDA-approved prescribing information, the general sequence is to reconstitute one vial with the supplied water, transfer that solution into the second vial so the two combine, mix gently by rolling rather than shaking, inspect for clarity, and withdraw the prescribed dose according to the manufacturer's prescribing information. The exact volumes and any updated steps should be confirmed against the current version of the label before use, since labeling can be revised.

Egrifta SV (second-generation formulation)

Egrifta SV consolidates the kit into a single 2 mg vial reconstituted with the diluent provided, using the same gentle-rolling technique and clarity check described in its FDA-approved labeling according to its prescribing information. Readers should treat any specific volume or timing instruction as provisional until checked against the label in hand, since this article does not reproduce the label verbatim.

Both brand products direct storage of the reconstituted solution under refrigeration and use within a short, defined window because the supplied diluent is sterile water without an antimicrobial preservative. The exact hour count should be read directly from the label dispensed with the product, since labeling has been revised across formulations and this figure is volatile enough that it should not be treated as fixed based on this article alone (verification required against the current label, checked as of 2025-01-28).

Bacteriostatic Water for Compounded Tesamorelin

Compounding pharmacies dispensing tesamorelin under a prescription commonly use bacteriostatic water, which contains benzyl alcohol as an antimicrobial preservative. This is standard practice for many injectable reconstitutions and is why compounded multi-dose vials can generally support longer in-use periods than the sterile-water brand kits. Bacteriostatic water is not appropriate for neonates and should be avoided in patients with known benzyl alcohol hypersensitivity.

The exact beyond-use date for a compounded tesamorelin vial is not something this article, or any general reference, can specify with confidence. Beyond-use dating for compounded sterile preparations is governed by USP sterile compounding standards, which set conditions under which a pharmacy may assign an extended dating period (USP General Chapter <797>). The pharmacy-assigned date on your specific vial's label is the only number that should be relied upon, and it can be shorter than a commonly cited 28-day figure depending on the pharmacy's own stability testing.

Choosing a Reconstitution Volume

The volume of bacteriostatic water added determines concentration. Common clinical targets include:

A 1 mg/mL concentration keeps the arithmetic simplest: 10 units = 0.10 mL = 0.10 mg. A 2 mg/mL concentration halves injection volume, which some patients find more comfortable, but it doubles the consequence of any unit-reading error.

Dosing Math, Step by Step

Step 1. Confirm the vial concentration. Read the pharmacy label for mg/mL. If it is not stated, call the pharmacy before drawing anything.

Step 2. Calculate the volume for a 2 mg dose.

• At 1 mg/mL: 2 mg ÷ 1 mg/mL = 2.0 mL
• At 2 mg/mL: 2 mg ÷ 2 mg/mL = 1.0 mL

Step 3. Convert to syringe units.

• 2.0 mL × 100 = 200 units (needs a 2 mL or 3 mL syringe, not a standard 0.5 mL or 1 mL insulin syringe)
• 1.0 mL × 100 = 100 units (fills a standard 1 mL U-100 syringe)

A standard 0.5 mL U-100 insulin syringe holds only 50 units. If a 1 mg/mL vial requires 2.0 mL for a 2 mg dose, that will not fit in a 0.5 mL or even a 1 mL syringe without splitting the injection. This is a common reason clinicians prescribing compounded tesamorelin favor a 2 mg/mL concentration for a 2 mg daily dose: it keeps the injection to a single 1.0 mL draw.

Reference Table

Recalculate every time a new vial arrives. Compounding pharmacies can and do dispense different concentrations across refills depending on vial availability, and the syringe itself gives no warning that the concentration has changed.

Injection Technique

The FDA-approved injection site is the abdomen, with rotation across the abdominal region and avoidance of the navel, scars, bruises, and any lipodystrophy-affected tissue, per FDA labeling. Injection technique details such as needle gauge, angle, and hold time are generally consistent with standard subcutaneous self-injection practice used for other injectable peptides and insulin, but any specific gauge or timing recommendation should be confirmed with the prescribing clinician or pharmacy rather than treated as a fixed protocol here.

Before every injection, confirm three things: the solution is clear and colorless (discard if cloudy or particulate), the vial is within its labeled use window or beyond-use date, and the calculated dose matches the syringe marking. These checks take under a minute and address the most common administration errors.

What the Evidence Actually Establishes

Established (FDA-approved indication and label): Tesamorelin, as Egrifta or Egrifta SV, is approved for reducing excess visceral adipose tissue in adults with HIV-associated lipodystrophy at 2 mg subcutaneously once daily, reconstituted per the manufacturer's instructions in the current FDA label as described in the manufacturer's current prescribing information.

Plausible but requiring verification against the current label or primary trial reports: Specific numeric efficacy figures (percentage reduction in visceral fat, incidence of new-onset glucose intolerance, magnitude of triglyceride change) are commonly cited in secondary sources describing the pivotal trials for tesamorelin. This article does not reproduce those figures because the identifiers available for this draft could not be independently confirmed as pointing to the correct papers. A clinician or editor with direct access to the trial publications or the FDA label's clinical studies section should verify any specific percentage before it is published as fact.

Not established: Compounded tesamorelin is not an FDA-approved finished product; its quality, concentration accuracy, and beyond-use dating depend on the individual compounding pharmacy and are not backed by the same review process as the branded product. Off-label use of tesamorelin for general body-composition goals outside HIV-associated lipodystrophy is not supported by FDA-reviewed evidence presented in the approved label.

Clinician-Discussion and Monitoring Framework

Refer to this framework when discussing tesamorelin therapy with your prescribing clinician or pharmacist, recognizing it complements rather than replaces personalized dosing guidance. This outline distinguishes between FDA-established parameters and considerations unique to your clinical presentation and compounded formulation.

Checkpoint 1: Before the first reconstitution

• Confirm in writing what concentration (mg/mL) the dispensed vial is meant to produce once reconstituted.
• Confirm which diluent (sterile water vs. bacteriostatic water) the pharmacy intends and why.
• Ask what beyond-use date applies to this specific vial, and whether it differs from a generic "28 days" figure.
• Escalate to the pharmacy, not a guess, if the label does not state mg/mL clearly.

Checkpoint 2: At the first dose

• Verify the calculated volume and syringe units against the formula (dose ÷ concentration = volume; volume × 100 = units) with a second person if possible, especially for a 200-unit draw that requires a non-standard syringe.
• Confirm baseline labs the clinician wants tracked (commonly a baseline IGF-1 and metabolic panel in tesamorelin therapy, though the exact monitoring schedule should come from the prescribing clinician rather than this article).
• Document injection site and any immediate reaction.

Checkpoint 3: Early follow-up (timeframe set by the prescriber, commonly within the first 1 to 2 months)

• Review whether the concentration on any refilled vial matches the original, since compounding pharmacies can change vial fill or dilution volume between refills.
• Report new or worsening joint pain, swelling, numbness or tingling in the hands, or unusual fluid retention, which can reflect excess GH/IGF-1 activity and warrants clinician contact rather than dose self-adjustment.
• Report new symptoms of hyperglycemia (increased thirst, frequent urination, blurred vision), since GHRH analogs can reduce insulin sensitivity in some patients.

Stop-and-escalate conditions (contact the prescribing clinician or seek urgent care, not a forum or a peer):

• Cloudy, discolored, or particulate-containing reconstituted solution.
• Signs of a local injection-site infection: increasing redness, warmth, swelling, or pus.
• Symptoms suggestive of a significant allergic reaction: hives, facial or throat swelling, difficulty breathing.
• Uncertainty about the current vial's concentration before a dose is drawn. When in doubt, do not inject; call the pharmacy.
• Any dose drawn or injected that is recognized, after the fact, to be a multiple of the intended amount (for example, drawing 200 units when 100 was intended). This should be reported to the clinician promptly rather than self-managed.

Where label guidance ends and individualized care begins

• The FDA label defines the approved dose, indication, and the brand kit's reconstitution steps. It does not define compounded-product concentrations, individualized beyond-use dates, or dose adjustments for a specific patient's IGF-1 trend; those are matters of pharmacy practice and clinical judgment made by the prescriber.
• This article cannot substitute for that individualized judgment. It is a framework for asking the right questions, not a protocol to follow independently.

Frequently Asked Questions